MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) has launched a website for MOXATAG (extended-release amoxicillin) Tablets, 775 mg. MOXATAG is the first and only FDA-approved once-daily amoxicillin, and now healthcare professionals and patients have access to a comprehensive online resource for information about treating pharyngitis and tonsillitis, also known as strep throat, with MOXATAG at http://www.moxatag.com.
Visitors to the MOXATAG website can learn about the causes, symptoms and treatment of pharyngitis and tonsillitis. A video shows how MiddleBrook’s proprietary drug delivery technology, PULSYS®, prolongs the release and absorption of amoxicillin from MOXATAG to effectively treat bacterial pharyngitis and tonsillitis at a daily dose of 775 mg, which is lower than currently prescribed aminopenicillin therapies. The site also features an informative FAQ section, complete product prescribing information and information for pharmacists.
MiddleBrook President and CEO John Thievon said, "MOXATAG is a unique product with no AB-rated generic, and MOXATAG has valuable benefits for patients and prescribers. The MOXATAG website showcases MOXATAG’s attributes and illustrates the compliance-enhancing benefits of once-daily dosing.”
"A review of the latest available data indicates that approximately 3,000 prescriptions have been filled for MOXATAG through April 24, with steady week-over-week growth,” Thievon continued. "This is in line with our expectations, given launch timing and the seasonality of pharyngitis and tonsillitis, and we anticipate more than half of the total 2009 MOXATAG prescription volume to be generated in the fourth quarter. The MOXATAG.com website will support the efforts of our national field sales force and serve as a valuable adjunct to our nationwide print media campaign directed at healthcare professionals as we work to increase awareness for MOXATAG, the first and only FDA-approved once-daily amoxicillin.”
No comments:
Post a Comment